India, April 28 -- Oruka Therapeutics, Inc. (ORKA), has priced an upsized $700.4 million underwritten public offering, strengthening its balance sheet as the company advances two late-stage dermatology programs designed for ultra-infrequent dosing chronic skin diseases.
The offering includes 9.66 million shares of common stock priced at $72.50 per share, with underwriters holding a 30-day option to purchase up to 1.45 million additional shares. The financing is expected to close on or around April 30, 2026, subject to customary conditions.
Leerink Partners, TD Cowen, Goldman Sachs Stifel and Guggenheim Securities are acting as joint bookrunning managers, with LifeSci Capital serving as a passive bookrunner.Oruka said the proceeds will sup...